Shares of Athenex Inc (NASDAQ:ATNX) have been assigned a consensus broker rating score of 2.00 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Athenex’s rating score has declined by 33.3% from three months ago as a result of a number of analysts’ upgrades and downgrades.

Brokerages have set a 1-year consensus price objective of $25.73 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 109 out of 265 based on the ratings given to its competitors.

Several equities analysts recently commented on the stock. J P Morgan Chase & Co assumed coverage on shares of Athenex in a research report on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price target for the company. Laidlaw assumed coverage on shares of Athenex in a research report on Tuesday, September 19th. They set a “buy” rating and a $36.00 price target for the company. Credit Suisse Group assumed coverage on shares of Athenex in a research report on Monday, September 18th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Royal Bank of Canada assumed coverage on shares of Athenex in a research report on Thursday, September 14th. They set an “outperform” rating and a $35.00 price target for the company.

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new position in Athenex during the third quarter worth approximately $198,000. Schwab Charles Investment Management Inc. acquired a new position in Athenex during the third quarter worth approximately $524,000. Bank of New York Mellon Corp increased its position in Athenex by 106.7% during the third quarter. Bank of New York Mellon Corp now owns 31,002 shares of the company’s stock worth $543,000 after purchasing an additional 16,002 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new position in Athenex during the third quarter worth approximately $1,559,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Athenex in the second quarter worth $601,000. 2.93% of the stock is owned by hedge funds and other institutional investors.

Athenex (NASDAQ ATNX) opened at $16.83 on Friday. Athenex has a one year low of $11.21 and a one year high of $20.79.

ILLEGAL ACTIVITY WARNING: “Zacks: Athenex Inc (ATNX) Given Consensus Rating of “Buy” by Analysts” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/16/zacks-athenex-inc-atnx-given-consensus-rating-of-buy-by-analysts.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Stock Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related stocks with our FREE daily email newsletter.